Hosted by Theral Timpson · 🇺🇸 US · EN · 550 episodes
Established thought leaders with verified media credentials.
Offering a front row seat to the Century of Biology, veteran podcast host Theral Timpson interviews the who's who in genomics and genomic medicine. www.mendelspod.com
Theral Timpson hosts Mendelspod Podcast, a science show with 550 episodes published.
On today’s show, Dr. Ryan Flynn of Harvard Medical School and Boston Children’s Hospital takes us into a newly emerging layer of biology: the architecture of the cell surface itself. Flynn first gained attention for the
For decades, biology has been driven by the powerful notion that if we could sequence enough genomes, transcriptomes, epigenomes, then we could finally explain the cell. On today’s show, Gary Schroth, the Chief Scientifi
Today on the show, we’re discussing a new study just presented at ASCO 2026 that could change how chemotherapy decisions are made for a large group of breast cancer patients. During ASCO we spoke with Phil Febbo, Chief S
For years, precision oncology has largely been discussed through the lens of breakthrough drugs. But there’s another story running underneath modern cancer care: the quiet rise of companion diagnostics. These tests are i
Dr. Eric Green returns to Mendelspod in a new role: Chief Medical Officer of Illumina. After more than three decades at the National Human Genome Research Institute, where he helped guide genomics from research initiativ
This is a free preview of a paid episode. To hear more, visit www.mendelspod.com For years, proteomics was described as the missing layer of biology. Why missing? Because measuring proteins at scale turned out to be vast
We’ve gotten very good at reading DNA. We’re just beginning to understand how to read its state. On today’s show, Rob Osborne, Senior Vice President of R&D at Biomodal, discusses new evidence that separating two epigenet
This is a free preview of a paid episode. To hear more, visit www.mendelspod.com On today’s show, a fascinating discussion about digital twins for medical research— leading to the 64 million dollar question of how much o
An inventor of Solexa sequencing by synthesis has a new idea. On today’s show, Sir Shankar Balasubramanian revisits the accidental origins of Solexa sequencing, born not from a sequencing project at all, but from curiosi
There’s a famous line attributed to Ernest Rutherford, the father of nuclear physics: “All science is either physics or stamp collecting.” It’s still provocative. But it’s unfair to biology. Long before today’s omics era
You’ve heard of 5-base genomics. How about 6-base? It turns out that separating 5-methylcytosine (mC) and 5-hydroxymethylcytosine (hmC) is pretty important. Peter Fromen has had a front-row seat to the evolution of seque
What is the value of someone’s genome over their life? Is a genome today what it was 10 years ago? How does the adoption of genomic testing compare to other areas in medicine, such as imaging or electronic health records
Fei Chen of the Broad Institute describes the original problem simply: genomics gave us powerful inventories of gene expression, while microscopy gave us structure—yet the two lived in separate worlds. “You could either
Peptides are having a moment. But beneath the market excitement and the GLP-1 headlines, something more interesting is going on. A field that for years seemed technically promising but perpetually constrained is becoming
It was the biggest story in sequencing last year: Mark Kokoris, head of SBX sequencing at Roche and inventor of the technology, joins Mendelspod to talk about how Sequencing by Expansion (SBX) works and why it may redefi
Why do some animals live ten times longer than others? That question opens today’s interview with Steve Austad, Distinguished Professor at the University of Alabama at Birmingham and one of the leading thinkers in the bi
Molecular residual disease, or MRD, has been part of oncology’s vocabulary for decades. But knowing something is there and being able to measure it precisely are two very different things. In today’s show, we explore how
This is a free preview of a paid episode. To hear more, visit www.mendelspod.com For two decades, tests like Oncotype DX have helped oncologists decide which early-stage breast cancer patients should receive chemotherapy
We began this podcast back around the time the ENCODE project announced that much of the genome was biochemically active. The big science project was undoing the tidy idea of “junk DNA,” and not without controversy. But
“We have been talking now for 15, 20 years about the diagnostic odyssey. That shouldn’t exist anymore. The new odyssey is the therapeutic odyssey.” That’s Stephen Kingsmore, president and CEO of Rady Children’s Hospital
Sponsor detection runs nightly. Check back soon.
No public pitch examples yet for this show.
Generate your own personalised pitchBased on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:
Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.
Shows with the most semantically similar episode content. Pitch one, pitch all; producers cluster.
Mendelspod Podcast has a verified contact on file. Create a free PitchCentric account to access it and generate a personalised pitch in seconds. Research at least 3 recent episodes first and lead with a specific angle that serves their science audience.
Mendelspod Podcast is hosted by Theral Timpson. The show is categorised under science (medicine) and has published 550 episodes.
Mendelspod Podcast has published 550 episodes.
Mendelspod Podcast regularly covers science, medicine, natural. It sits in the science category, with a medicine focus.
Mendelspod Podcast is accessible for guests with genuine science expertise. A personalised, episode-aware pitch will still outperform a generic one every time.
Mendelspod Podcast hasn't explicitly signalled guest openness in recent episodes. That doesn't rule out pitching. your hook just needs to be especially compelling and relevant to their recent content.
Episodes of Mendelspod Podcast average 30 minutes. a focused format where a clear narrative arc and tight preparation matter most.
Our data rates Mendelspod Podcast's guest bar at 80/100 (Premium tier). Established thought leaders with verified media credentials. Sign in to PitchCentric to see how your own Pod Score compares against this show.
Methodology. Booking Probability™ blends Listen Score, 30-day Virality, open-to-guests detection, and Apple ratings. Data refreshed every 60 minutes. Listen Score and Booking Probability are calculated by PitchCentric. Last enriched 7 days ago.
